Literature DB >> 10416531

The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine.

A Mocroft1, S Barry, C A Sabin, A C Lepri, S Kinloch, A Drinkwater, M Lipman, M Youle, M A Johnson, A N Phillips.   

Abstract

OBJECTIVE: To describe the changes over time in incidence of hospital admissions among patients with HIV, reasons for hospital admission, duration of stay, relationship with CD4 T-cell count and with antiretroviral treatment.
METHODS: The incidence of hospital admissions during each calendar year from 1988 to 1997 inclusive was calculated using a person-years analysis. In addition the proportion of patient follow-up spent in hospital and the impact of changing treatment regimens among all patients with HIV aged > or = 14 years and with at least one CD4 T-cell count seen at the Royal Free Hospital, London was also described.
RESULTS: A total of 1806 patients were investigated with median follow-up of 21.1 months. Among all patients, the proportion of follow-up time spent as an in-patient decreased from 3.9% in 1988 to 1.3% in 1997 (P = 0.0015; test for trend). Hospital admissions for any cause peaked during 1989 at 72.0 per 100 patient years of follow-up (PYFU) and was 28.5 per 100 PYFU during 1997 (P < 0.0001; test for trend). There was a statistically significant decline in the proportion of follow-up time spent as an in-patient among patients with CD4 T-cell counts of < 50 x 10(6)/l from > 30% before 1990 to < 5% during 1997 (P = 0.026; test for trend). Hospital admissions varied greatly according to treatment regimen; in 1996 and 1997 just 0.1% of follow-up time of patients on triple antiretroviral treatment regimens was spent as a hospital admission.
CONCLUSIONS: Admissions to hospital began falling before the introduction of combination therapy and declined strikingly during 1996 and 1997 following the introduction of highly active antiretroviral therapy. These results have important implications for future allocation of resources and for patient management.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416531     DOI: 10.1097/00002030-199907090-00016

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  14 in total

1.  Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?

Authors:  Nancy F Crum-Cianflone; Greg Grandits; Sara Echols; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Robert Barthel; Brian Agan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

2.  Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.

Authors:  Wolfgang Resch; Neil Parkin; Terri Watkins; Janera Harris; Ronald Swanstrom
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Hospitalizations in a cohort of HIV patients in Australia, 1999-2007.

Authors:  Kathleen Falster; Handan Wand; Basil Donovan; Jonathan Anderson; David Nolan; Kerrie Watson; Jo Watson; Matthew G Law
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

4.  Hospitalization rates of people living with HIV in the United States, 2009.

Authors:  Marcus A Bachhuber; William N Southern
Journal:  Public Health Rep       Date:  2014 Mar-Apr       Impact factor: 2.792

5.  Hospitalization risk following initiation of highly active antiretroviral therapy.

Authors:  S A Berry; Y C Manabe; R D Moore; K A Gebo
Journal:  HIV Med       Date:  2009-12-08       Impact factor: 3.180

6.  Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001.

Authors:  Monique M R de Maat; Teun M Post; Daniël M Jonker; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Cornelis H W Koks; Anthonius de Boer; Jos H Beijnen
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

7.  Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.

Authors:  Marcel Zwahlen; Ross Harris; Margaret May; Robert Hogg; Dominique Costagliola; Frank de Wolf; John Gill; Gerd Fätkenheuer; Charlotte Lewden; Mike Saag; Sholmo Staszewski; Antonella d'Arminio Monforte; Jordi Casabona; Fiona Lampe; Amy Justice; Viktor von Wyl; Matthias Egger
Journal:  Int J Epidemiol       Date:  2009-10-09       Impact factor: 7.196

8.  Characterizing the immune system after long-term undetectable viral load in HIV-1-infected children.

Authors:  Salvador Resino; Isabel Galán; José M Bellón; M Luisa Navarro; Juan Antonio León; M Angeles Muñoz-Fernandez
Journal:  J Clin Immunol       Date:  2003-07       Impact factor: 8.317

9.  Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.

Authors:  Ross J Harris; Jonathan A C Sterne; Sophie Abgrall; François Dabis; Peter Reiss; Michael Saag; Andrew N Phillips; Geneviève Chêne; John M Gill; Amy C Justice; Jürgen Rockstroh; Caroline A Sabin; Amanda Mocroft; Heiner C Bucher; Robert S Hogg; Antonella D'Arminio Monforte; Margaret May; Matthias Egger
Journal:  Antivir Ther       Date:  2008

10.  Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

Authors:  Michael J Mugavero; Margaret May; Ross Harris; Michael S Saag; Dominique Costagliola; Matthias Egger; Andrew Phillips; Huldrych F Günthard; Francois Dabis; Robert Hogg; Frank de Wolf; Gerd Fatkenheuer; M John Gill; Amy Justice; Antonella D'Arminio Monforte; Fiona Lampe; Jose M Miró; Schlomo Staszewski; Jonathan A C Sterne
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.